Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Amgen

Here's What to Expect From Amgen’s Next Earnings Report

Amgen is scheduled to report its third-quarter earnings next month, and analysts forecast a modest single-digit decline in profits.

Barchart

The Best Biotech ETFs to Buy

Biotech ETFs offer investors exposure to the most innovative and growth-oriented industry within the traditionally defensive healthcare sector.

Kiplinger

The Saturday Spread: 3 Beaten-Down Stocks Making a Statistical Case for a Comeback

Here’s an innovative approach to deciphering which red-stained stocks are actually worth a look for bullish contrarians.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Biopharma Stocks Rally After Trump Threatens 100% Pharmaceuticals Tariff

President Donald Trump delivered the pharmaceutical industry another blow this week, threatening 100% tariffs on some companies.

Investors Business Daily

Is Amgen Stock Underperforming the S&P 500?

Analysts continue to favor Amgen stock, despite its relative underperformance to the broader S&P 500 Index.

Barchart

BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up

BeOne Medicines Ltd. (NASDAQ:ONC) on Monday agreed to sell its royalty rights on the worldwide sales, excluding China, of Amgen Inc.’s (NASDAQ:AMGN) Imdelltra (tarlatamab-dlle) for up to $950 million to Royalty Pharma Inc. (NASDAQ:RPRX).

Benzinga

Stock Market Rises In Range; Palantir, AMD, Shopify Lead Huge Earnings Movers: Weekly Review

The stock market indexes had big weekly gains despite some daily swings. Palantir and Shopify were among huge earnings movers.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Amgen Stock Sinks As Market Eyes MariTide's Next Move

Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that surpassed analyst expectations after markets closed on Tuesday.

Benzinga

Why S&P 500 Stock Amgen Stumbled Despite Its Beat-And-Raise Quarter

Amgen stock dropped Wednesday despite a strong second quarter as investors look ahead to the next weight-loss readouts.

Investors Business Daily

Stock Index Futures Gain on Strong Earnings and Fed Rate-Cut Bets

September S&P 500 E-Mini futures (ESU25) are up +0.24%, and September Nasdaq 100 E-Mini futures (NQU25) are up +0.30% this morning, extending a rebound driven by bets on Federal Reserve interest rate cuts and solid corporate earnings.

Barchart

Do Wall Street Analysts Like Amgen Stock?

Amgen has notably outpaced the broader market and the healthcare sector in 2025, and analysts remain cautiously optimistic about the stock’s prospects.

Barchart

Dow Leads as Merck, Amgen Gain: Stock Market Today

Second-quarter earnings season remained top of mind Tuesday, with Coca-Cola and GM among those reporting.

Kiplinger

Earnings Preview: What to Expect From Amgen’s Report

Amgen is set to release its second-quarter earnings next month, and analysts are projecting modest single-digit growth in profit.

Barchart

Amgen: How To Find And Own America's Greatest Opportunities

From Amgen's classic double-bottom base in February 1990 until it ultimately topped in the summer of 2000, it increased more than 50 times.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?

Protagonist Therapeutics is taking aim directly at Eli Lilly's obesity treatment with a newly announced drug that uses the same mechanism.

AAP

Career blocks for female scientists put under scrutiny

Talented female scientists are being pushed out of cancer research due to gender discrimination, ageism and an absence of mentorship, funding and job security.

Windows Central

Microsoft Copilot is "pretty important" but customers still prefer ChatGPT — "OpenAI has done a tremendous job"

A new report suggests that Microsoft's sales division is struggling to differentiate Copilot from ChatGPT, with customers preferring OpenAI's offering.

The Independent UK

New once-a-month drug could treat diabetes and obesity, scientists say

Researchers say experimental drug’s less frequent dosing could improve adherence and offer long-term control

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Amgen Hammered As 'Tough' Obesity Meeting Reminds It It's Not The Incumbent

Amgen presented promising results for its weight-loss drug. But not everyone is convinced.

Barchart

How Is Amgen's Stock Performance Compared to Other Pharmaceuticals Stocks?

Amgen has underperformed the Pharmaceuticals industry over the past year, but analysts are moderately optimistic about the stock’s prospects.

Investors Business Daily

The Next Look At Amgen's Obesity Drug Is Coming. Here's What Investors Are Watching.

Later this month, the Street will have a fresh opportunity to gauge the potential for Amgen's experimental weight-loss drug, MariTide.

Kiplinger

Stock Market Today: Nasdaq Outperforms as Big Tech Rallies

The Dow Jones Industrial Average closed lower for a second day as Amgen and Merck fell.

Investors Business Daily

S&P, Dow Pharma Stocks Boomerang On Drug-Pricing Order That Is 'All Bark' And 'Little Bite'

Pharmaceutical stocks boomeranged Monday after Trump signed an executive order tying drug prices in the U.S. to international price tags.

Investors Business Daily

12 Stocks Blow Away Warren Buffett's Long-Term Track Record

Warren Buffett's Berkshire Hathaway sports an enviable long-term track record. But not even Buffett is No. 1 in the S&P 500 in the long run.

Barchart

Amgen Stock Outlook: Is Wall Street Bullish or Bearish?

Although Amgen has lagged behind the broader market over the past year, Wall Street analysts remain cautiously optimistic about the company’s long-term outlook.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.